ArticleNature communications2026
T2Pdecoder enables protein-centric analyses from transcriptomic data.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T2Pdecoder enables protein-centric analyses from transcriptomic data.Nature communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein quantification is not as extensive as RNA quantification, especially for isocitrate dehydrogenase (IDH) mutant gliomas. Predicting protein abundance from RNA is valuable for leveraging existing data to understand biological processes, though the weak correlation between RNA and protein poses a significant challenge. Most existing methods predict limited protein subsets from transcriptome, constraining their broader proteomic applications. Here, we present T2Pdecoder, an integrative multi-omics deep learning model designed to predict broad protein abundance profiles by learning the shared embedding space of protein and RNA. T2Pdecoder is evaluated on different glioma datasets, achieving modest but consistent improvements over RNA-only baselines in concordance with measured protein abundance, while more accurately recapitulating protein-level pathway enrichment patterns. The applications of T2Pdecoder on glioma bulk RNA data uncover functional subgroups with significant survival differences. Furthermore, T2Pdecoder reduces batch-associated variation in single-cell RNA data and identifies distinctive cell markers. Collectively, these results suggest that T2Pdecoder enables protein-centric analyses from transcriptomic data and may provide complementary biological insights beyond conventional RNA-only analyses in cancer research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.